After a transformative 2025 driven by positive data across its chronic cough programs, Trevi Therapeutics Inc. (TRVI) is gaining momentum and is now set to begin its first pivotal trial in IPF-related chronic cough this quarter.
Chronic cough is often the first symptom associated with idiopathic pulmonary fibrosis (IPF), a rare and progressive lung disease. Around 150,000 people in the U.S. have IPF. About 60-70% of those with IPF experience uncontrolled coughing, which can be severe, reaching up to 1,500 coughs per day. Currently, there are no approved treatments for chronic cough in IPF patients.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.